Home›Stock Screener›Bacil Pharma›Financial Statements

Bacil Pharma Complete Financial Statements

12 Years of Data
2026 - 2015

In FYNone, Bacil Pharma (BACPHAR) reported revenue ₹0 Cr, net profit ₹1 Cr and EPS ₹0.70, with a net profit margin of 200.0% and ROE of 8.0%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Bacil Pharma share price today.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 200.00% 2026 data
EBITDA Margin 100.00% 2026 data
Return on Assets 7.41% 2026 data
Return on Equity 8.00% 2026 data

Balance Sheet Ratios

Equity Ratio 92.59% 2026 data
Asset Turnover 0.04 2026 data

BACPHAR Revenue, Net Profit & EBITDA — Year-on-Year Growth

BACPHAR YoY (March 2026 vs Period) — revenue -100.0%, net profit -50.0%, EBITDA -100.0%.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-50.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Assets Growth
+3.8%
Year-over-Year
Financing Cash Flow Growth
-150.0%
Year-over-Year

BACPHAR Income Statement — Revenue, EBITDA & Net Profit

Bacil Pharma revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹1 Cr, EPS ₹0.70 (None) — net profit margin 200.0%. Compare with BACPHAR fair price to assess whether the stock is under or overvalued.

Periods ₹ Crores
Particulars None March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 0 1 1 0 0 0 0 0 0 0 0 0 0
Expenses 0 0 0 0 0 4 0 1 0 0 0 0 0
EBITDA 0 1 0 0 0 -4 0 0 0 0 0 0 0
Operating Profit Margin % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 1 0 0 0 -4 0 0 0 -4 0 0 0
Tax 0 -1 0 0 0 0 0 0 0 0 0 0 0
Net Profit 1 2 0 0 0 -4 0 0 0 -4 0 0 0
Earnings Per Share (₹) 0.70 1.11 0.64 -0.10 -0.17 -6.55 -0.41 -0.54 -0.58 -6.37 0.00 -0.11 -0.05

BACPHAR Balance Sheet — Assets, Liabilities & Shareholders' Equity

BACPHAR total assets ₹27 Cr, total equity ₹25 Cr, total liabilities ₹ Cr (2026) — ROE 8.0%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 27 26 1 1 1 4 4 5 5 7 7 7
Current Assets 2 3 0 0 0 0 0 1 1 0 0 1
Fixed Assets 0 0 0 0 0 3 3 3 3 6 5 0
Capital Work in Progress 0 0 0 0 0 0 0 0 0 0 0 6
Investments 24 21 1 0 0 0 0 1 1 1 0 0
Other Assets 3 4 1 1 1 1 1 1 1 0 1 1
LIABILITIES
Total Liabilities
Current Liabilities 0 0 0 0 0 0 0 0 0 0 0 0
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 25 25 1 1 1 1 1 2 2 6 6 7
Share Capital 14 14 7 7 7 7 7 7 7 7 7 7
Reserves & Surplus 11 12 -5 -5 -5 -5 -5 -5 -4 0 0 0

BACPHAR Cash Flow Statement — Operating, Investing & Financing

Bacil Pharma operating cash flow ₹1 Cr, investing ₹-2 Cr, financing ₹-1 Cr, net cash flow ₹-2 Cr (2026).

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 1 0 0 0 -4 0 0 0 1 0 0 0
Investing Activities -2 0 0 0 4 1 0 0 -1 0 0 0
Financing Activities -1 2 0 0 0 0 0 0 0 0 0 0
Net Cash Flow -2 3 0 0 0 0 0 0 0 0 0 0